ATP5PF

Across TCGA pan-cancer cohorts, ATP5PF mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ATP5PF data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ATP5PF mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP5PF expression acts as an unfavorable survival marker, although some lineages such as PDAC and OV show a favorable association.

HNSC, PDAC, and OV are the cancer types where ATP5PF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	II,III,IV	0.596	0.905	<.001	45	view →
PDAC	OS	Median	All	0.957	0.696	<.001	42	view →
OV	DFS	Quartile	All	1.000	0.452	.031	8	view →
GBM	DFS	Quartile	All	0.835	0.660	.007	4	view →
LUAD	OS	Median	All	0.612	0.837	.033	4	view →
CCRCC	OS	Median	All	0.984	0.906	.031	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ATP5PF–HNSC (DFS)

Open the HNSC breakdown →